Semax

Overview

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), a molecular weight of 813.97 Da, and the molecular formula C₃₇H₅₁N₉O₁₀S. Developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences by the research groups of Ivan P. Ashmarin and Nikolai F. Myasoedov, Semax is structurally based on the ACTH(4-7) fragment (Met-Glu-His-Phe) — the melanocortin core of adrenocorticotropic hormone — extended at the C-terminus with a stabilizing Pro-Gly-Pro tripeptide tail.

The Pro-Gly-Pro extension serves a critical pharmacological purpose: it blocks carboxypeptidases that would otherwise rapidly degrade the active ACTH fragment (which has a plasma half-life measured in seconds), providing sufficient metabolic stability for intranasal administration and nose-to-brain transport. Semax is registered as a pharmaceutical agent in Russia and is available as 0.1% and 1% nasal drop formulations for various neurological indications.

Mechanism of Action

Semax operates through multiple neurobiological pathways, with its most well-characterized mechanism involving the modulation of neurotrophic factor expression.

Brain-derived neurotrophic factor (BDNF) modulation represents the primary documented mechanism. Grivennikov et al. (PMID: 16635254) demonstrated that Semax binds specifically to rat basal forebrain tissue and increases BDNF protein levels. A single intranasal application at 50 mcg/kg body weight produces a 1.4-fold increase in BDNF protein levels accompanied by a 1.6-fold increase in TrkB tyrosine phosphorylation, a 3-fold increase in exon III BDNF mRNA, and a 2-fold increase in TrkB mRNA levels in the rat hippocampus (PMID: 16996037).

Semax also demonstrates melanocortin receptor activity without the hormonal effects of full-length ACTH, meaning it does not stimulate adrenal cortisol production. Additional mechanisms under investigation include modulation of cholinergic neurotransmission, regulation of nitric oxide synthase activity, and neuroprotective effects via reduction of oxidative stress markers.

Recent research has also identified Semax's capacity for copper(II) ion binding with high affinity (K_D = 2.4 nm), which may contribute to its protective effects against metal-induced neurotoxicity relevant to neurodegenerative conditions.

Research Evidence

The most substantial body of clinical evidence for Semax comes from Russian research institutions, where it has been studied extensively in cerebrovascular disease.

In a clinical trial of 110 ischemic stroke patients (PMID: 29798983), intranasal Semax administered at 6,000 mcg/day across two 10-day treatment courses raised plasma BDNF levels and produced measurable improvements in motor function scores and functional independence metrics.

Animal studies by Dolotov et al. (PMID: 16996037) established the molecular basis for Semax's neurotrophic effects, demonstrating regulation of BDNF and TrkB expression in the hippocampus following a single intranasal dose. Subsequent work (PMID: 19633950) showed that Semax activates transcription of neurotrophins and their receptor genes following experimental cerebral ischemia.

Neuroprotection studies by Bashkatova et al. (PMID: 17603664) demonstrated that Semax exhibits pronounced neuroprotective and antiamnesic effects during focal photoinduced ischemia of the prefrontal cortex, with 6-day intranasal administration decreasing cortical infarction volume and improving retention of conditioned passive avoidance responses.

Potential Applications

• Ischemic stroke: Approved in Russia for acute hemispheric ischemic stroke as a 1% nasal spray adjunct to standard therapy
• Cognitive enhancement: Investigation as a nootropic agent for attention, memory consolidation, and learning performance
• Optic nerve disease: Semax 1% nasal drops have been studied in optic nerve atrophy and glaucomatous optic neuropathy in Russian clinical settings
• Neurodegenerative disease research: Copper-binding properties and neurotrophic factor modulation suggest potential relevance to Alzheimer's disease pathology
• Stress adaptation: Preclinical evidence of anxiolytic effects and improved performance under cognitive stress conditions

Safety Considerations

Within the Russian pharmacopoeia, Semax has an established safety record spanning several decades of clinical use, with intranasal administration at standard doses (0.1% solution, 200-600 mcg per dose) reported as well tolerated. Adverse effects in clinical literature are uncommon and include occasional nasal mucosal irritation and mild headache.

However, several important caveats apply to the safety assessment. Nearly all human clinical data originates from Russian research groups, and no large-scale, multi-center, double-blind, placebo-controlled trials have been conducted in Western regulatory frameworks. Semax is not approved by the FDA, EMA, or any regulatory agency outside of Russia and some CIS countries. The absence of independent replication of clinical findings in diverse populations limits the generalizability of safety and efficacy data. Long-term safety data with chronic use remain sparse in the published literature.